Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications, a systematic review and meta-analysis

  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Vázquez, Juan Carlos
  • Ullmo, Johana|||0000-0002-9313-917X
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Evidence on the impact of low-molecular-weight heparin, alone or in combination with low-dose aspirin, for the prevention for preeclampsia in high-risk patients is conflicting. Objective: We conducted a meta-analysis of studies published to assess the effectiveness of low-molecular-weight heparin for the prevention of preeclampsia and other placenta-related complications in high-risk women. Data Sources: A systematic search was performed to identify relevant studies, using the databases PubMed and Cochrane Central Register of Controlled Trials, without publication time restrictions. Study Eligibility Criteria: Randomized controlled trials comparing treatment with low-molecular-weight heparin or unfractionated heparin (with or without low-dose aspirin), in high-risk women, defined as either history of preeclampsia, intrauterine growth restriction, fetal demise, or miscarriage or being at high risk after first-trimester screening of preeclampsia. Study Appraisal and Synthesis Methods: The systematic review was conducted according to the Cochrane Handbook guidelines. The primary outcome was the development of preeclampsia. We performed prespecified subgroup analyses according to combination with low-dose aspirin, low-molecular-weight heparin type, gestational age when treatment was started, and study population (patients with thrombophilia, at high risk of preeclampsia or miscarriage). Secondary outcomes included small for gestational age, perinatal death, miscarriage, and placental abruption. Pooled odds ratios with 95% confidence intervals were calculated using a random-effects model. Quality of evidence was assessed using the grading of recommendations assessment, development, and evaluation methodology. Results: A total of 15 studies (2795 participants) were included. In high-risk women, treatment with low-molecular-weight heparin was associated with a reduction in the development of preeclampsia (odds ratio, 0.62; 95% confidence interval, 0.43-0.90; P=.010); small for gestational age (odds ratio, 0.61; 95% confidence interval, 0.44-0.85; P=.003), and perinatal death (odds ratio, 0.49; 95% confidence interval, 0.25-0.94; P=.030). This reduction was stronger if low-molecular-weight heparin was started before 16 weeks' gestation (13 studies, 2474 participants) for preeclampsia (odds ratio, 0.55; 95% confidence interval, 0.39-0.76; P=.0004). When only studies including low-dose aspirin as an intervention were analyzed (6 randomized controlled trials, 920 participants), a significant reduction was observed in those with combined treatment (low-molecular-weight heparin plus low-dose aspirin) compared with low-dose aspirin alone (odds ratio, 0.62; 95% confidence interval, 0.41-0.95; P=.030). Overall, adverse events were neither serious nor significantly different. Quality of evidence ranged from very low to moderate, mostly because of the lack of blinding, imprecision, and inconsistency. Conclusion: Low-molecular-weight heparin use was associated with a significant reduction in the risk of preeclampsia and other placenta-mediated complications in high-risk women and when treatment was started before 16 weeks' gestation. Combined treatment with low-dose aspirin was associated with a significant reduction in the risk of preeclampsia compared with low-dose aspirin alone. However, there exists important clinical and statistical heterogeneity, and therefore, these results merit confirmation in large well-designed clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cardiovascular risk assessment in women at high risk for pre-eclampsia in first half of pregnancy

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Bos-Real, L.|||0000-0002-6159-0644
  • Padilla-Lopez, Mireia|||0000-0002-4374-3870
  • Coma-Barbarà, Marina
  • Martorell, Silvia
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Women diagnosed with pre-eclampsia (PE), especially those with early-onset and severe forms, are at heightened risk of future cardiovascular disease (CVD). It is uncertain if women at high-risk for PE present cardiovascular impairment at the beginning of pregnancy. The aim of this study was to assess cardiovascular biomarkers and cardiac function in the first half of pregnancy in women at high-risk for PE. Methods: This was a prospective cohort study including women attending first trimester screening for PE. Risk of PE in the first trimester was calculated using a previously validated model, which includes maternal factors and biophysical markers. A cut-off of 1 in 250 was used to classify high-risk for developing PE. Maternal echocardiographic function and morphometry were evaluated, and peripheral blood samples were obtained to assess hematological and biochemical variables, including lipid profile and cardiovascular and angiogenic factors. Results: A total of 349 pregnant individuals were included; 257 at high-risk and 92 at low-risk for PE. Maternal echocardiography was performed at a mean ± SD gestational age of 14.9 ± 1.3 weeks and blood sampling at 16.3 ± 1.9 weeks. The high-risk PE group exhibited a significantly worse lipid profile (lower levels of high-density lipoproteins 69.7 ± 14.2 vs 74.0 ± 14.6 mg/dL, p=0.020), lower placental growth factor (0.89 ± 0.63 vs 1.15 ± 0.58 MoM, p<0.001), and significantly lower levels of N-terminal pro-brain natriuretic peptide (51.0 ± 2.1 vs 52.1 ± 2.0 ng/L, p=0.008). Echocardiographic evaluation indicated concentric remodeling, along with an altered diastolic pattern in the high-risk group. Conclusions: Women at high risk of developing PE exhibit differences in lipid profile, angiogenic factors, and echocardiographic parameters, indicative of cardiac maladaptation or impairment during the first half of pregnancy. These findings suggest a link between subclinical cardiovascular dysfunction, PE development and later CVD risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ophthalmic artery Doppler and carotid intima-media thickness 3-6 years postpartum in women with and without a history of placental insufficiency

  • García Manau, Pablo|||0000-0002-2415-1626
  • Platero, Judit|||0000-0001-6007-9855
  • Costa, Noah
  • Garcia, Zoraida
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Pellicer, Claudia
  • Ullmo, Johana|||0000-0002-9313-917X
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Jordi, Mariona
  • Choliz, Marta
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Trilla, Cristina|||0000-0002-5650-1790
  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Llurba, Elisa|||0000-0003-4048-6407
Preeclampsia and fetal growth restriction, which are clinical presentations of placental dysfunction, are frequently associated with angiogenic imbalance during pregnancy and increased long-term cardiovascular risk. Whether this risk is driven by the pre-pregnancy risk factors, clinical disease, or by an elevated sFlt-1/PlGF ratio remains unclear. This study aimed to assess the association between vascular assessments (ophthalmic artery Doppler and carotid intima-media thickness) 3-6 years postpartum and a history of preeclampsia and fetal growth restriction, and to evaluate if associations were impacted by an angiogenic imbalance during pregnancy. This was a cross-sectional study, which included individuals prospectively recruited during their index pregnancy between 2018 and 2021 and re-evaluated 3-6 years postpartum. Preeclampsia, fetal growth restriction, and sFlt-1/PlGF values were defined from pregnancy data. Postpartum assessment included ophthalmic artery Doppler and carotid intima-media thickness performed by a single operator. Multivariable linear regression models assessed associations between placental dysfunction, angiogenic imbalance, and vascular parameters, adjusting for maternal covariates. 354 participants were included, 148 with and 206 without a history of preeclampsia or fetal growth restriction. Both placental dysfunction and angiogenic imbalance during pregnancy were independently associated with a significantly higher ophthalmic artery peak systolic velocity ratio 3-6 years postpartum. Participants with a history of placental dysfunction showed higher values compared to those without [0.75 (0.67-0.81) vs. 0.69 (0.63-0.78), p = 0.03], as did those with an elevated sFlt-1/PlGF ratio during pregnancy [0.76 (0.66-0.82) vs. 0.70 (0.64-0.78), p = 0.03]. The highest values were observed in women who had experienced both conditions. When preeclampsia and fetal growth restriction were analyzed separately, the association remained significant for preeclampsia, whereas in the fetal growth restriction group, a significant difference was observed only in the right eye. No statistically significant differences were observed in carotid intima-media thickness. Both a history of angiogenic imbalance and a clinical placental dysfunction presentation (particularly preeclampsia) during pregnancy were associated with increased ophthalmic artery peak systolic velocity ratio 3-6 years postpartum, whereas carotid intima-media thickness did not differ between the study groups. Both angiogenic imbalance and a history of placental dysfunction during pregnancy are associated with increased ophthalmic artery peak systolic velocity ratio 3-6 years postpartum, especially in cases where clinical disease (particularly preeclampsia) develops.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Biochemical and Cardiovascular Profiles 3-6 Years After Preeclampsia, Impact of Angiogenic Imbalance During Pregnancy

  • Costa, Noah
  • Platero, Judit|||0000-0001-6007-9855
  • García Manau, Pablo|||0000-0002-2415-1626
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Jordi, Mariona
  • García Ruiz, Zoraida|||0009-0009-4631-763X
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Ullmo, Johana|||0000-0002-9313-917X
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Choliz, Marta
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
  • Pellicer, Claudia
  • Medina Mallen, Maria del Carmen|||0000-0002-1219-5947
Background/Objectives: Preeclampsia is associated with long-term cardiovascular and metabolic risks. This study aimed to evaluate metabolic and cardiovascular biochemical profiles in women with a history of preeclampsia and angiogenic imbalance during pregnancy. Methods: We conducted a cross-sectional study at Hospital de la Santa Creu i Sant Pau between August 2023 and July 2025. Participants had been prospectively enrolled during pregnancy (2018-2022) and were re-evaluated 3 to 6 years later. Blood and urine samples were collected after a 12-h fast to assess hematological, metabolic, and cardiovascular markers. Angiogenic profiles were determined using sFlt-1/PlGF ratios obtained during pregnancy. Multivariable linear regression models were used to assess associations with a history of PE and angiogenic imbalance, adjusting for relevant confounders. Results: 363 participants were included. 113 (31.1%) had a history of preeclampsia. Women with previous preeclampsia showed slightly higher high-sensitivity troponin T concentrations [4.0 (3.0-6.0) ng/L vs. 3.2 (3.0-5.0) ng/L, p = 0.03]. Women with sFlt-1/PlGF ≥38 exhibited significantly higher urinary protein [0.09 (0.07-0.18) g/L vs. 0.08 (0.07-0.13) g/L, p = 0.01], potassium [4.25 (4.07-4.40) mmol/L vs. 4.19 (4.02-4.37) mmol/L, p = 0.048], and LDH concentrations [168 (150-189) U/L vs. 163 (149-177) U/L, p = 0.046], and lower leukocyte counts [6150 (5348-7055) vs. 6250 (5430-7450) U/mL, p = 0.03]. Conclusions: Women with angiogenic imbalance during pregnancy display subtle alterations in renal and endothelial function markers years after delivery, whereas those with preeclampsia show slightly higher troponin concentrations. These findings, though clinically irrelevant, suggest that pregnancy-related vascular dysfunction may have different long-term manifestations depending on whether the maternal cardiovascular system was sufficiently compromised to develop overt preeclampsia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications

  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Universitat Autònoma de Barcelona.
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Platero, Judit|||0000-0001-6007-9855
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • García Manau, Pablo|||0000-0002-2415-1626
  • Ullmo, Johana|||0000-0002-9313-917X
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Vila-Cortés, M.
  • Pelegay, M. J.
  • Ricart, M
  • Muñoz-Abellana, B.
  • Barrios, X. Gabaldó
Objective: A soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio cut-off of 38 is currently considered optimal for ruling out pre-eclampsia (PE); however, implementation of this ratio in clinical practice is limited. N-terminal pro B-type natriuretic peptide (NT-proBNP) is elevated in PE owing to the cardiovascular effects of this disease. This study aimed to identify the predictive performance of NT-proBNP to detect PE and placental complications within 1 week after assessment, and compare it with the predictive performance of the sFlt-1/PlGF ratio. High-sensitivity troponin T (hs-TnT) and uric acid were also evaluated. Methods: This was a prospective nested case-control study conducted in five Spanish centers between March 2018 and December 2020, and comprised women with a singleton pregnancy and suspected PE between 24 + 0 and 41 + 0 weeks' gestation. We evaluated the ability of the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid to predict the development of any-onset (at any gestational age), early-onset (before 34 weeks) or term (at or after 37 weeks) PE within 1 week or 4 weeks after assessment. Predictive performance was assessed by estimating negative predictive values, positive predictive values, sensitivity, specificity and areas under the receiver-operating-characteristics curves (AUCs) for these biomarkers, with corresponding 95% CIs. We performed post-hoc exploratory analyses of associations between the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid in women who developed PE, as well as in women who developed complicated PE (PE plus fetal growth restriction, stillbirth or placental abruption) within 1 week and 4 weeks after assessment. Results: A total of 323 women with suspected PE at or before 41 + 0 weeks were enrolled in the study, of whom seven were lost to follow-up. The final analysis included 316 eligible participants, with 424 samples. The overall incidence of PE was 23.4% (n = 74) and early-onset PE developed in 8.5% (n = 27) of cases. The sFlt-1/PlGF ratio and NT-proBNP exhibited similar abilities to predict early-onset PE within 1 week after assessment (AUC, 0.970 (95% CI, 0.932-1.000) and 0.971 (95% CI, 0.942-1.000), respectively). hs-TnT and uric acid demonstrated inferior predictive capability compared with the sFlt-1/PlGF ratio for the prediction of any-onset PE, early-onset PE and term PE within 1 week and 4 weeks after assessment. The optimal cut-off for NT-proBNP was 116 pg/mL. At this cut-off, NT-proBNP showed a sensitivity of 90.9% (95% CI, 70.8-98.9%) and a specificity of 94.3% (95% CI, 91.2-96.5%), with a positive predictive value of 5.7% (95% CI, 3.7-8.7%) and a negative predictive value of 99.9% (95% CI, 99.9-100%) in predicting early-onset PE within 1 week of assessment, which was comparable with that of the sFlt-1/PlGF ratio. Participants with PE-related complications had higher levels of all biomarkers, but only NT-proBNP showed a similar predictive ability to the sFlt-1/PlGF ratio for complicated PE within 1 week after assessment (AUC, 0.818 (95% CI, 0.706-0.930) vs 0.822 (95% CI, 0.723-0.921), respectively). Conclusion: An NT-proBNP cut-off value of 116 pg/mL has a similar diagnostic performance to that of the sFlt-1/PlGF ratio in predicting the diagnosis of early-onset PE within 1 week after assessment. Thus, NT-proBNP could be used in clinical practice for the early identification and management of PE, particularly in cases for which the sFlt-1/PlGF ratio is not available. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers

  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Álvarez Menéndez, Francisco V.|||0000-0002-2553-5402
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Carretero, Francisco
  • Fernández-Oliva, Antonio|||0000-0002-8610-2600
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Sánchez García, Olga|||0000-0002-5279-440X
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Alijotas-Reig, Jaume|||0000-0002-9212-3619
  • Llurba, Elisa|||0000-0003-4048-6407
N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) to predict PE in patients with clinical suspicion, and evaluate if the model performed better than the sFlt-1/PlGF ratio alone. A multicentric cohort study of pregnancies with suspected PE between 24 +0 and 36 +6 weeks was used. The MLM included six predictors: gestational age, chronic hypertension, sFlt-1, PlGF, NT-proBNP, and uric acid. A total of 936 serum samples from 597 women were included. The PPV of the MLM for PE following 6 weeks was 83.1% (95% CI 78.5-88.2) compared to 72.8% (95% CI 67.4-78.4) for the sFlt-1/PlGF ratio. The specificity of the model was better; 94.9% vs. 91%, respectively. The AUC was significantly improved compared to the ratio alone [0.941 (95% CI 0.926-0.956) vs. 0.901 (95% CI 0.880-0.921), p < 0.05]. For prediction of preterm PE within 1 week, the AUC of the MLM was 0.954 (95% CI 0.937-0.968); significantly greater than the ratio alone [0.914 (95% CI 0.890-0.934), p < 0.01]. To conclude, an MLM combining the sFlt-1/PlGF ratio, NT-proBNP, and uric acid performs better to predict preterm PE compared to the sFlt-1/PlGF ratio alone, potentially increasing clinical precision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Longitudinal Behavior of Left-Ventricular Strain in Fetal Growth Restriction

  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Ginjaume García, Nuria|||0000-0003-0785-0115
  • Ullmo, Johana|||0000-0002-9313-917X
  • Fernández-Oliva, Antonio|||0000-0002-8610-2600
  • Parra Roca, Juan|||0000-0001-6011-7815
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
Fetal growth restriction (FGR) is associated with an increased risk of adverse outcomes resulting from adaptive cardiovascular changes in conditions of placental insufficiency, leading to cardiac deformation and dysfunction, which can be evaluated with 2D speckle tracking echocardiography (2D-STE). The aim of the present study was to evaluate whether reduced fetal growth is associated with cardiac left-ventricle (LV) dysfunction, using 2D-STE software widely used in postnatal echocardiography. A prospective longitudinal cohort study was performed, and global (GLO) and segmental LV longitudinal strain was measured offline and compared between FGR and appropriate-for-gestational-age (AGA) fetuses throughout gestation. All cases of FGR fetuses were paired 1:2 to AGA fetuses, and linear mixed model analysis was performed to compare behavior differences between groups throughout pregnancy. Our study shows LV fetal longitudinal strain in FGR and AGA fetuses differed upon diagnosis and behaved differently throughout gestation. FGR fetuses had lower LV strain values, both global and segmental, in comparison to AGA, suggesting subclinical cardiac dysfunction. Our study provides more data regarding fetal cardiac function in cases of placental dysfunction, as well as highlights the potential use of 2D-STE in the follow-up of cardiac function in these fetuses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fetal Left Ventricle Function Evaluated by Two-Dimensional Speckle-Tracking Echocardiography across Clinical Stages of Severity in Growth-Restricted Fetuses

  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Ginjaume García, Nuria|||0000-0003-0785-0115
  • Ullmo, Johana|||0000-0002-9313-917X
  • Parra Roca, Juan|||0000-0001-6011-7815
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
Fetal growth restriction (FGR) can result in adverse perinatal outcomes due to cardiac dysfunction. This study used 2D speckle-tracking echocardiography to assess left ventricle (LV) longitudinal strain across FGR severity stages. A prospective longitudinal cohort study measured global (GLS) and segmental LV longitudinal strain in FGR fetuses, with evaluations conducted at various time points. FGR was classified into subtypes based on published criteria using fetal weight centile and Doppler parameters. A linear mixed model was employed to analyze repeated measures and compare Z-score measurements between groups throughout gestational age. The study included 40 FGR fetuses and a total of 107 evaluations were performed: 21 from small for gestational age (SGA), 74 from the FGR stage I, and 12 from the FGR stage ≥ II. The results indicate that SGA and stage I FGR fetuses exhibit higher LV GLS than stages ≥ II. Throughout gestation, SGA and FGR stage I fetuses showed similar behavior with consistently better LV GLS values when compared to FGR stages ≥ II. No significant differences were observed in LV GLS strain behavior between SGA and FGR stage I. In conclusion, all FGRs show signs of early cardiac dysfunction, with severe cases demonstrating significantly a lower LV GLS when compared to mild cases, suggesting deterioration of cardiac dysfunction with progression of fetal compromise.